Pardeep Nijhawan has bought EDSA on 6 days since Mar 2021

Pardeep Nijhawan, MD, FRCPC, AGAF, age 54, is the Chief Executive Officer, Corporate Secretary, and a director of Edesa Biotech, Inc. (EDSA) since June 7, 2019. He founded Edesa Biotech Research in January 2015, which became a key part of the company's pipeline development, and has over 20 years of experience in life sciences leadership spanning finance, marketing, strategy, and business development.(

Nijhawan holds an MD from the University of Ottawa, completed an internship at Yale, and finished an internal medicine residency and fellowship at the Mayo Clinic. His career highlights include founding and successfully exiting Medical Futures Inc. (sold to Tribute Pharmaceuticals in 2015), Exzell Pharma (sold to BioLab Pharma in 2022), and Digestive Health Clinic, where he continues as a board member. He recently demonstrated confidence in Edesa Biotech through personal investments, including direct and indirect purchases of company shares in early 2026 (e.g., 10,000 shares on March 3 at $3.63 via his professional corporation, 3,000 shares on March 2) and 100 Series B-1 Preferred shares for $1.0M on February 12, 2025, holding approximately 19.99% ownership.(

Written by Perplexity from public sources.